ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

ACS Research Grants Hit $78.2 Million

July 18, 1986

Grossman Leads Neuro-Oncology Society; NYU Recruits Radiation Oncology Director.

January 14, 2000

In Brief: Georgetown Professor Heads Cancer Therapy Evaluation Program; NCI-VA Branch Abolished

September 7, 1979

ACS’ Freeman; Declare New War In Cancer; Poor Get Substandard Treatment, Lost Dignity

July 21, 1989

DCT To Examine Groups’ Studies, Directions, Role in 2000 A.D. Goal

June 8, 1984

DCT Board reluctantly Okays Resources Contracts Recompetition, $6 of $10 Million Competitively

April 1, 1977